cure drpla
  • Home
  • ABOUT
    • About DRPLA
    • Who We Are
  • CURRENT INITIATIVES
    • Global Patient Registry
    • Patient & Caregiver
    • Researchers & Industry
  • News and Announcements
    • Announcements
    • News Articles
    • Events
  • Français
  • Italiano
  • Português
  • 日本語
  • 한국어
What is it like to participate in a research study for DRPLA?

What is it like to participate in a research study for DRPLA?

by Silvia Prades | Sep 21, 2023 | News Articles

CureDRPLA is currently funding a Natural History and Biomarkers Study, aimed at gaining a deeper understanding of the progression of DRPLA over time, as well as identifying any genetic factors and markers that might predict disease progression. This study will provide...
DRPLA Researchers Spotlight – Dr Jeff Carroll’s group at UW

DRPLA Researchers Spotlight – Dr Jeff Carroll’s group at UW

by Silvia Prades | Sep 13, 2023 | News Articles

It is time we created a space for our funded researchers to shine and acknowledge publicly their tremendous contributions to the field. This will be an ongoing feature in which we will introduce all our funded researchers from around the world to our readers. The...
Building meaningful connections at the International Movement Disorders Congress

Building meaningful connections at the International Movement Disorders Congress

by Silvia Prades | Sep 6, 2023 | News Articles

CureDRPLA was a proud exhibitor at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, held from August 27-31. This event drew in a remarkable crowd of over 5,200 in-person attendees representing more than 100 countries. This...

Sign up for CureDRPLA newsletter

by Silvia Prades | Aug 16, 2023 | Announcements

Be among the first to know and become part of our community. Sign up here.
Support NAF in asking the FDA to incorporate regulatory flexibility when evaluating drug applications for rare diseases

Support NAF in asking the FDA to incorporate regulatory flexibility when evaluating drug applications for rare diseases

by Silvia Prades | Aug 16, 2023 | News Articles

The FDA, the US regulatory agency for new medicines, declined to review the documents for a potential therapy for SCA3 (type of ataxia) developed by Biohaven. The criteria for approving a drug often rely on standards established for more prevalent conditions, making...
« Older Entries

Recent Posts

  • What is it like to participate in a research study for DRPLA?
  • DRPLA Researchers Spotlight – Dr Jeff Carroll’s group at UW
  • Building meaningful connections at the International Movement Disorders Congress
  • Sign up for CureDRPLA newsletter
  • Support NAF in asking the FDA to incorporate regulatory flexibility when evaluating drug applications for rare diseases

Recent Comments

    Andrea Compton

    President & Co-Founder

    Paul Compton

    Co-Founder

    info@cureDRPLA.org

    cureDRPLA.org

    @cureDRPLA

    Andrea Compton

    Register at Rare Connect

    cure drpla

    Contact Us


    info@cureDRPLA.org

    Helping Families and Individuals Worldwide

    Thank you for visiting our site. Please be in touch with us personally to share your story or any relevant information. Together, we may be able to develop a better understanding and potential treatments or a cure for DRPLA.

    • Home
    • About DRPLA
    • Who We Are
    • Global Patient Registry
    • Patient & Caregiver
    • Researchers & Industry
    • Events
    • Donate
    • English
      • English
      • Français
      • Italiano
      • Português
      • 日本語
      • 한국어

    Copyright © 2021 CureDRPLA. All rights reserved.